Deutsche Bank
ADPT icon

Deutsche Bank’s Adaptive Biotechnologies ADPT Stock Holding History

Deutsche Bank’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.26M Sell
216,505
-20,901
-9% -$513K ﹤0.01% 1150
2026
Q2 		$5.09M Sell
237,406
-548,377
-70% -$8.4M ﹤0.01% 1366
2026
Q1 		$10.9M Sell
785,783
-948,682
-55% -$15.1M ﹤0.01% 1026
2025
Q4 		$28.2M Buy
1,734,465
+21,326
+1% +$348K 0.01% 789
2025
Q3 		$25.6M Buy
1,713,139
+1,542,685
+905% +$18.8M 0.01% 784
2025
Q2 		$1.99M Sell
170,454
-447,721
-72% -$4.07M ﹤0.01% 1713
2025
Q1 		$4.59M Sell
618,175
-12,402
-2% -$95.3K ﹤0.01% 1286
2024
Q4 		$3.78M Buy
630,577
+503,842
+398% +$2.78M ﹤0.01% 1477
2024
Q3 		$649K Sell
126,735
-458,968
-78% -$2M ﹤0.01% 2321
2024
Q2 		$2.12M Sell
585,703
-18,803
-3% -$59.7K ﹤0.01% 1605
2024
Q1 		$1.94M Buy
604,506
+1,450
+0.2% +$5.61K ﹤0.01% 1678
2023
Q4 		$2.95M Buy
603,056
+546,069
+958% +$2.49M ﹤0.01% 1480
2023
Q3 		$311K Sell
56,987
-540,190
-90% -$3.57M ﹤0.01% 2490
2023
Q2 		$4.01M Sell
597,177
-37,886
-6% -$282K ﹤0.01% 1322
2023
Q1 		$5.61M Buy
635,063
+12,345
+2% +$109K ﹤0.01% 1197
2022
Q4 		$4.76M Sell
622,718
-31,335
-5% -$244K ﹤0.01% 1235
2022
Q3 		$4.66M Buy
654,053
+5,651
+0.9% +$53.2K ﹤0.01% 1240
2022
Q2 		$5.25M Buy
648,402
+306,982
+90% +$2.7M ﹤0.01% 1258
2022
Q1 		$4.74M Buy
341,420
+206,421
+153% +$3.25M ﹤0.01% 1450
2021
Q4 		$3.79M Sell
134,999
-22,012
-14% -$675K ﹤0.01% 1605
2021
Q3 		$5.34M Buy
157,011
+10,922
+7% +$395K ﹤0.01% 1469
2021
Q2 		$5.97M Sell
146,089
-18,711
-11% -$727K ﹤0.01% 1420
2021
Q1 		$6.64M Buy
164,800
+125,067
+315% +$6.77M ﹤0.01% 1401
2020
Q4 		$2.35M Sell
39,733
-113,601
-74% -$5.86M ﹤0.01% 1831
2020
Q3 		$7.46M Buy
153,334
+107,309
+233% +$4.51M 0.01% 1085
2020
Q2 		$2.23M Sell
46,025
-359,678
-89% -$13.1M ﹤0.01% 1734
2020
Q1 		$11.3M Buy
405,703
+384,326
+1,798% +$10.7M 0.01% 871
2019
Q4 		$637K Buy
21,377
+13,750
+180% +$395K ﹤0.01% 2609
2019
Q3 		$235K Buy
+7,627
New +$311K ﹤0.01% 3093

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Deutsche Bank's ADPT Position: Q3 2026 in Review

Deutsche Bank reduced its Adaptive Biotechnologies (ADPT) stake by 8.8% in Q3 2026, selling an estimated $513K and leaving 216,505 shares worth $6.26M. The position accounts for ﹤0.01% of the portfolio, ranked #1150.

Deutsche Bank first reported a position in ADPT in Q3 2019 and has held it in 29 quarters since. The position peaked at $28.2M in Q4 2025. 154 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Deutsche Bank held 216,505 shares of Adaptive Biotechnologies worth $6.26M as of Q3 2026.
  • Deutsche Bank sold 20,901 Adaptive Biotechnologies shares in Q3 2026, an estimated $513K.
  • Adaptive Biotechnologies made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #1150 holding.
  • Deutsche Bank first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 29 quarters since.
  • Deutsche Bank's Adaptive Biotechnologies position peaked at $28.2M in Q4 2025.
  • 154 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.